Physician profile
Jonathan D Hunter
NPI 1619969532
$10,940.02
in general payments reported to CMS, 2019-2025
56 companies · $1,115 in 2025
The $1,115 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,324 · 2020: $1,998 · 2021: $1,613 · 2022: $1,180 · 2023: $1,704 · 2024: $1,006 · 2025: $1,115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,824.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,204.45 | 2021-2025 | |
| Novo Nordisk INC | $1,128.49 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $967.72 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $705.68 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $598.80 | 2019-2025 | Farxiga, Breztri |
| Amgen INC. | $591.34 | 2019-2025 | Repatha, Otezla, Evenity |
| Allergan, INC. | $572.08 | 2019-2020 | |
| Pfizer INC. | $376.12 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $305.62 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $290.84 | 2019-2024 | Trintellix |
| Amarin Pharma, INC. | $276.50 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $235.66 | 2019-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.96 | 2019-2023 | Xifaxan |
| Mylan Specialty L.P. | $196.64 | 2019-2023 | Yupelri |
| Corcept Therapeutics | $171.57 | 2022-2025 | Korlym |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.